Brian Powl - Jan 2, 2024 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Commercial Officer
Signature
Teresa Bair, Attorney-in-fact for Brian Powl
Stock symbol
KURA
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:07 PM
Previous filing
Aug 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +15K $0.00 15K Jan 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +30K $0.00 30K Jan 2, 2024 Common Stock 30K $15.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28.
F2 This option vests in 48 equal monthly installments commencing on the grant date.